STAT News

STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials

An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.

By STAT News

1 min read
STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights